Linsidomine

This classification denotes a vasodilating agent and nitric oxide-releasing compound, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5O5U71P6VQ. European Medicines Agency schedules Linsidomine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08524MIG. Linsidomine generally arises in the molecular formula C6H10N4O2. The term LINSIDOMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, no. 3, 1988, list 28.) LINSIDOMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule linsidomine under HS 29349990 and SITC 51579. As of Q4 2014, LINSIDOMINE remains the US FDA Preferred Term for this commodity. Linsidomine bears US NLM identifiers UMLS ID C0525082 and NCI Concept Code C72628. SMILES: O1CCN([n]2[nH]oc(=N)c2)CC1.